Etravirine

Joost Vermeulen; Marc van der Valk

doi:https://doi.org/10.1201/9781315152110

Etravirine

Joost Vermeulen, Marc van der Valk

Research output: Chapter in Book/Report/Conference proceeding › Chapter › Academic › peer-review

1 Citation (Scopus)

Abstract

The nonnucleoside reverse transcriptase inhibitor etravirine (previous investigational names R165335 and TMC125) is a diarylpyrimidine (DAPY) derivative (see Figure 238.1) and is a potent and highly specific inhibitor of the reverse transcriptase of the human immunodeficiency virus type 1 (HIV-1). In limited studies, it has shown significantly weaker activity against HIV-2.

Original language	English
Title of host publication	Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition
Publisher	CRC Press
Pages	3970-3988
ISBN (Electronic)	9781498747967
ISBN (Print)	9781498747950
DOIs	https://doi.org/10.1201/9781315152110
Publication status	Published - 2017

Publication series

Name	Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition

Access to Document

https://doi.org/10.1201/9781315152110

Cite this

Vermeulen, J., & van der Valk, M. (2017). Etravirine. In Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition (pp. 3970-3988). (Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition). CRC Press. https://doi.org/10.1201/9781315152110

@inbook{1f7bf583a2d844beb24cc6973dee539f,

title = "Etravirine",

abstract = "The nonnucleoside reverse transcriptase inhibitor etravirine (previous investigational names R165335 and TMC125) is a diarylpyrimidine (DAPY) derivative (see Figure 238.1) and is a potent and highly specific inhibitor of the reverse transcriptase of the human immunodeficiency virus type 1 (HIV-1). In limited studies, it has shown significantly weaker activity against HIV-2.",

author = "Joost Vermeulen and {van der Valk}, Marc",

year = "2017",

doi = "https://doi.org/10.1201/9781315152110",

language = "English",

isbn = "9781498747950",

series = "Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition",

publisher = "CRC Press",

pages = "3970--3988",

booktitle = "Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition",

}

Vermeulen, J & van der Valk, M 2017, Etravirine. in Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition, CRC Press, pp. 3970-3988. https://doi.org/10.1201/9781315152110

Etravirine. / Vermeulen, Joost; van der Valk, Marc.
Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. CRC Press, 2017. p. 3970-3988 (Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition).

Research output: Chapter in Book/Report/Conference proceeding › Chapter › Academic › peer-review

TY - CHAP

T1 - Etravirine

AU - Vermeulen, Joost

AU - van der Valk, Marc

PY - 2017

Y1 - 2017

N2 - The nonnucleoside reverse transcriptase inhibitor etravirine (previous investigational names R165335 and TMC125) is a diarylpyrimidine (DAPY) derivative (see Figure 238.1) and is a potent and highly specific inhibitor of the reverse transcriptase of the human immunodeficiency virus type 1 (HIV-1). In limited studies, it has shown significantly weaker activity against HIV-2.

AB - The nonnucleoside reverse transcriptase inhibitor etravirine (previous investigational names R165335 and TMC125) is a diarylpyrimidine (DAPY) derivative (see Figure 238.1) and is a potent and highly specific inhibitor of the reverse transcriptase of the human immunodeficiency virus type 1 (HIV-1). In limited studies, it has shown significantly weaker activity against HIV-2.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85056684740&origin=inward

U2 - https://doi.org/10.1201/9781315152110

DO - https://doi.org/10.1201/9781315152110

M3 - Chapter

SN - 9781498747950

T3 - Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition

SP - 3970

EP - 3988

BT - Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition

PB - CRC Press

ER -

Vermeulen J, van der Valk M. Etravirine. In Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. CRC Press. 2017. p. 3970-3988. (Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition). doi: https://doi.org/10.1201/9781315152110

Etravirine

Abstract

Publication series

Access to Document

Other files and links

Cite this